Anti-OX40 Antibody Combined with HBc VLPs Delays Tumor Growth in a Mouse Colon Cancer Model

CONCLUSION: Combination therapy of anti-hOX40 and HBc VLPs provides synergistic antitumor activity in colon cancer-bearing mice, which may represent a potential design strategy for cancer immunotherapy.PMID:38582981 | DOI:10.3967/bes2024.019

Source: Biomedical and Environmental Sciences : BES - April 7, 2024 Category: Biomedical Science Authors: Jia Jia Liu Qiu Dong Su Yao Yi Li Ping Shen Sheng Li Bi Source Type: research